Clinical study
Theophylline toxicity: Clinical features of 116 consecutive cases

https://doi.org/10.1016/0002-9343(90)90519-JGet rights and content

Abstract

purpose: To examine the predisposing factors, clinical and laboratory characteristics, management, course, and outcome of consecutive cases of theophylline toxicity in an outpatient setting.

patients and methods: Toxicology records and hospital charts of consecutive patients with a serum theophylline concentration (STC) greater than 30 mg/L (167 μmol/L) identified in the emergency departments (EDS) of a University Medical Center and a Veterans Administration Medical Center were reviewed.

results: Ten percent and 2.8% of 5,557 consecutive STCs measured in the EDs over 2 years were greater than 20 mg/L (111 μmol/L) and greater than 30 mg/L (167 μmol/L), respectively. One hundred sixteen cases with STC greater than 30 mg/L were identified. Fourteen (12%) and 102 (88%) were due to acute overdose and chronic overmedication, respectively. Principal predisposing factors included patient and/or physician dosing errors and conditions or medications that reduce theophylline clearance. One or more toxic manifestations were present in 109 (94%) cases. Fifty percent of patients had mild toxicity, 38% had moderate toxicity, and 7% had severe or life-threatening toxicity. Seven (6%) patients died when STC was still in the toxic range and/or as a result of toxicity. Acute overdose was associated with higher peak STC (p <0.001), younger age (p <0.01), and greater mortality (p <0.05) than chronic overmedication. Peak STC correlated significantly with the severity of toxicity for patients with acute overdose (p <0.01) but not for patients with chronic overmedication. All three patients with acute overdose and fatal toxicity had peak STCs greater than 100 mg/L (555 μmol/L) and fulminant toxicity, whereas the four patients with chronic overmedication who died during toxicity had peak STCs in the 40 to 60 mg/L (222 to 333 μmol/L) range and most died of respiratory failure rather than directly from toxicity. Patients with acute overdose who had the delayed onset of severe or life-threatening toxicity and/or died from toxicity were accurately identified using previously published criteria for prophylactic charcoal hemoperfusion. In contrast, the predictive value of the criteria applied to patients with chronic overmedication was poor. Two patients with acute overdose underwent charcoal hemoperfusion, but died. No patient with chronic overmedication received charcoal hemoperfusion.

conclusion: Toxic-range STCs are relatively common in the ED population, occur primarily as a result of patient and physician dosing errors, and cause a broad range of toxic manifestations of varying severity. Peak STC correlates with the severity of toxicity and outcome for acute overdose but not chronic overmedication intoxication. Previously published criteria for prophylactic charcoal hemoperfusion accurately identify patients with acute overdose but not patients with chronic overmedication at risk for serious complications and death.

References (60)

  • TL Litovitz et al.

    The role of hemoperfusion and hemodialysis in toxicology

    Am J Emerg Med

    (1988)
  • BC Corser et al.

    Prolonged toxicity following massive ingestion of sustained-release theophylline preparation

    Chest

    (1985)
  • CN Sessler et al.

    Treatment of theophylline toxicity with oral activated charcoal

    Chest

    (1985)
  • CN Sessler

    Poor tolerance of oral activated charcoal with theophylline overdose

    Am J Emerg Med

    (1987)
  • MD Baker

    Theophylline toxicity in children

    J Pediatr

    (1986)
  • P Gaudreault et al.

    Acute pediatric theophylline overdose: a summary of 28 cases

    J Pediatr

    (1983)
  • Y Amitai et al.

    Hypokalemia in acute theophylline poisoning

    Am J Emerg Med

    (1988)
  • Y Morita et al.

    Theophylline increases serum uric acid levels

    J Allergy Clin Immunol

    (1984)
  • JB MacDonald et al.

    Rhabdomyolysis and acute renal failure after theophylline overdose

    Lancet

    (1985)
  • KB Modi et al.

    Theophylline poisoning and rhabdomyolysis

    Lancet

    (1985)
  • M Bukowsky et al.

    Theophylline reassessed

    Ann Intern Med

    (1984)
  • TH Rossing

    Methylxanthines in 1989

    Ann Intern Med

    (1989)
  • MB Marks

    Theophylline: primary or tertiary drug?

  • NS Hill

    The use of theophylline in “irreversible” chronic obstructive pulmonary disease: an update

    Arch Intern Med

    (1988)
  • B Littenberg

    Aminophylline treatment in severe, acute asthma: a meta-analysis

    JAMA

    (1988)
  • L Hendeles et al.

    Theophylline: a “state of the art” review

    Pharmacotherapy

    (1983)
  • L Hendeles et al.

    Frequent toxicity from IV aminophylline infusions in critically ill patients

    Drug Intell Clin Pharm

    (1977)
  • WS Burkle et al.

    Evaluation of “toxic” serum theophylline concentrations

    Am J Hosp Pharm

    (1981)
  • HW Kelly

    Theophylline toxicity

  • P Gaudreault et al.

    Theophylline poisoning: pharmacological considerations and clinical management

    Med Toxicol

    (1986)
  • Cited by (107)

    • In silico and in vitro ADME-Tox analysis and in vivo pharmacokinetic study of representative pan-PDE inhibitors from the group of 7,8-disubstituted derivatives of 1,3-dimethyl-7H-purine-2,6-dione

      2022, Toxicology and Applied Pharmacology
      Citation Excerpt :

      Following i.v. dosing (the time point close to Cmax) that ranged from 0.04 to 1.56 μM and were relatively low compared to the IC50 values obtained in cytotoxicity analysis. It is known that toxic levels of TEO in humans are considered to be higher than 111.01 μM (Sessler, 1990). The concentrations attained in this study in mouse serum were much lower and after the highest i.p. dose slightly exceeded 30 μM for 38.

    • Decrease of the affinity of theophylline bind to serum proteins induced by flavonoids and their synergies on protein conformation

      2018, International Journal of Biological Macromolecules
      Citation Excerpt :

      It is a methylxanthine drug used in therapy for bronchial asthma, emphysema, bronchitis and cardiac dyspnea [1,2]. Because of its very narrow therapeutic index, the excessive serum theophylline concentrations usually lead to serious side effects, including nausea, nervousness, tachycardia, tachyarrhythmias, seizures, and shock [3]. Generally, the therapeutic serum concentrations of theophylline are from 10 to 20 mg/L [3,4].

    • Potentially harmful drug-drug interactions in the elderly: A review

      2011, American Journal Geriatric Pharmacotherapy
      Citation Excerpt :

      Unlike the other fluoroquinolones, ciprofloxacin appears to inhibit the CYP1A2-mediated metabolism of theophylline, resulting in elevated theophylline concentrations.66–69 Theophylline toxicity ranges from nausea, tremor, and headache to life-threatening seizures and cardiac arrhythmias.70,71 Risk factors for toxicity include the use of alcohol, hypothyroidism, chronic liver disease, and congestive heart failure.72

    View all citing articles on Scopus
    View full text